RE: flexy? anything moreFirst of all, this is primarily a discovery. More like Penicillin than the Xerox copier which is an invention.
What is its potential? Let's look at EdenBioscience. 25 million shares outstanding, sold in November at $43 a share of a market capitalization over one billion US, presently trading at US $16 or a market cap of 400 million US. IBR has a market cap of about 18 million US. The market place evaluates EdenBioscience as being worth 22 times as much as IBR. They have one product which they extract from a weed in a fermentation process. Through this process, they are able to extract a particular one-cell protein which protects some plants against some diseases to some degree when sprayed on leaves. I believe they currently are losing about a million a month. They sell this product, I believe, for 4.50 US an ounce. In my opinion, it is not possible for any realistic person to equate this company and its prospects with IBR.
However, EdenBioscience is sponsored by Merrill Lynch and IBR is sponsored by Canacord. Now this will change. IBR will obtain higher quality sponsorship, more likely sooner than later. As far as the business of IBR, I believe the overseas Chinese will take care of Asia. The momentum has reached a point where it will carry itself. The problem is North-America, primarily USA. The key is Massachusetts and the plant proposed for Oxbridge. This has been mentioned for some time in releases. Since Mass. through the STEP alliance is tied to New York, New Jersey and Pennsylvania in the East, Illinois in the Midwest, and California in the west, Mass becomes key to opening the dike. In addition, Mass. was the financial center of the US long before New York was and it still is a center for mutual funds which makes a plant in the suburbs of Boston so important for a launch of the IBR technology stateside.
As far as my opinion on the price of the stock, it is a very difficult stock for me to read on a week to week basis. If you have a time horizon of one year or more, I consider this stock to be the best start-up company buy I have ever seen at its present price. In other terms,the risk reward ratio is off the charts.